These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6614895)

  • 41. Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.
    Van der Auwera P; Husson M; Klastersky J
    J Antimicrob Chemother; 1988 Jan; 21(1):49-55. PubMed ID: 3128521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of polymorphonuclear leukocyte function against gram-positive aerobic organisms grown in the presence of lincomycin.
    Bassaris HP; Lianou PE; Votta EG; Skoutelis T; Papavassiliou T
    Infection; 1984; 12(6):369-71. PubMed ID: 6519809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human polymorphonuclear leukocyte interaction with cyclosporine A.
    Weinbaum DL; Kaplan SS; Zdziarski U; Rinaldo CR; Schroeder KK
    Infect Immun; 1984 Mar; 43(3):791-4. PubMed ID: 6365783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nocardicin A, a new monocyclic beta-lactam antibiotic III. In vitro evaluation.
    Nishida M; Mine Y; Nonoyama S; Kojo H
    J Antibiot (Tokyo); 1977 Nov; 30(11):917-25. PubMed ID: 412823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of bioflavonoids on phagocytosis, intracellular bactericidal activity and chemotaxis of human polymorphonuclear cells.
    Pruzanski W; Nitzan DW; Saito S
    Asian Pac J Allergy Immunol; 1983 Dec; 1(2):97-103. PubMed ID: 6681014
    [No Abstract]   [Full Text] [Related]  

  • 46. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
    Kuriyama T; Karasawa T; Nakagawa K; Nakamura S; Yamamoto E
    Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa.
    Eng RH; Smith SM; Cherubin C
    Antimicrob Agents Chemother; 1984 Jul; 26(1):42-7. PubMed ID: 6433787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Susceptibility of Alcaligenes denitrificans subspecies xylosoxydans to beta-lactam antibiotics.
    Mensah K; Philippon A; Richard C; Névot P
    Eur J Clin Microbiol Infect Dis; 1990 Jun; 9(6):405-9. PubMed ID: 2387293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
    Wise R; Andrews JM; Danks G
    Antimicrob Agents Chemother; 1983 Dec; 24(6):909-14. PubMed ID: 6607032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The in-vitro activity of ceftazidime: comparison with other beta-lactam antibiotics.
    Vanhoof R; Gordts B; Coignau H; Stas G; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():63-6. PubMed ID: 19802970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bactericidal activities of new beta-lactam antibiotics against Bacteroides fragilis.
    Yu PK; Washington JA
    Antimicrob Agents Chemother; 1983 Jul; 24(1):1-4. PubMed ID: 6625551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro activity of cefotetan, other beta-lactams and netilmicin.
    Shah PM
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():73-8. PubMed ID: 6573326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.
    Klempner MS; Noring R; Mier JW; Atkins MB
    N Engl J Med; 1990 Apr; 322(14):959-65. PubMed ID: 2156163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of tumor necrosis factor-alpha, interleukin-1 beta, and antibiotics on the killing of intracellular Staphylococcus aureus.
    Sanchez MS; Ford CW; Yancey RJ
    J Dairy Sci; 1994 May; 77(5):1251-8. PubMed ID: 8046066
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.
    Rolston KV; Chandrasekar PH; LeFrock JL; Schell RF
    Chemotherapy; 1984; 30(1):31-4. PubMed ID: 6420119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A turbidimetric study of the responses of selected strains of Pseudomonas aeruginosa to eight antipseudomonal beta-lactam antibiotics.
    Greenwood D; Eley A
    J Infect Dis; 1982 Jan; 145(1):110-7. PubMed ID: 6459389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
    Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
    Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 60. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.